The development program has been terminated
A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
Sponsor study identifier
interventional
100
1 country
21
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2006
Actual (reported)Study Completion
June 2006
Actual (reported)This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a 2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week follow-up period
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 28, 2005
Actual (reported)September 30, 2005
Actual (reported)June 2006
Actual (reported)June 2006
Actual (reported)Effects of on tubular secretion of creatinine in type 2 diabetics after 12 weeks of treatment as assessed through determinations of:
Glomerular filtration rate (GFR) by iothalamate clearance
Endogenous creatinine clearance
Effects of on tubular secretion of creatinine in type 2 diabetics after 24 weeks of treatment as assessed through determinations of:
GFR by iothalamate clearance
Endogenous creatinine clearance
The time course of change in serum creatinine concentration and GFR during a 24-week period of tesaglitazar treatment in type 2 diabetics
The effects of tesaglitazar on urinary protein excretion in type 2 diabetics by comparisons of urinary total protein and albumin excretion rates
2 mg once daily in oral form
45 mg once daily in oral form
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Research Site
Pasadena, California, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Gainesville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Columbus, Georgia, United States
Galida Medical Science Director, MD
AstraZeneca
First Submitted
September 28, 2005
First Posted
September 30, 2005
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2006
Actual (reported)Study In People With Type 2 Diabetes
Contact the study team to confirm eligibility.
Research Site
New Orleans, Louisiana, United States
Research Site
Reno, Nevada, United States
Research Site
Flushing, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Tulsa, Oklahoma, United States
Research Site
Cheswick, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Nashville, Tennessee, United States
Research Site
Midland, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Gig Harbor, Washington, United States
Research Site
Seattle, Washington, United States
Study Completion
June 2006
Actual (reported)Last Updated
August 30, 2011
Record last verified: 2011-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: